

Supplementary Table S1: Detailed Search Strategy

Database	Search String
PubMed MEDLINE 299 Results	((("Cardiomyopathy, Hypertrophic"[Mesh]) OR (Hypertrophic Cardiomyopathies)) OR (Hypertrophic Obstructive Cardiomyopathies)) OR (Hypertrophic Obstructive Cardiomyopathy)) AND (((((mavacamten) OR ("MYK-461" [Supplementary Concept])) OR (Aficamten)) OR (CK-274)) OR (Cardiac myosin inhibitors))
clinicaltrials.gov 28 Results	Hypertrophic Cardiomyopathy Aficamten OR Aficamten \ (CK-3773274\) (5 mg, 10 mg, 15 mg and 20 mg\) OR Mavacamten OR cardiac myosin inhibitor OR MYK-461
Cochrane Library 96 Results	Cardiomyopathy, Hypertrophic MeSH AND cardiac myosin inhibitor OR Mavacamten OR MYK-461 OR Aficamten OR CK-274 OR CK-3773274

Supplementary Table S2: PICO Table, Inclusion & Exclusion Criteria

Patient	Hypertrophic Cardiomyopathy
Intervention	Cardiac Myosin Inhibitors either Mavacamten or Aficamten
Control	Placebo drug
Outcome	<p>Primary outcomes:</p> <ul style="list-style-type: none"> • change in resting LVOT gradient • change in post-Valsalva LVOT gradient • change in left ventricular ejection fraction (LVEF) <p>Secondary outcomes:</p> <ul style="list-style-type: none"> • change in N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) • change in cardiac troponin I • proportion of patients achieving NYHA class improvement ≥ 1 • change in KCCQ-CSS
Study Design	Randomized controlled trials
Inclusion Criteria	<ul style="list-style-type: none"> • RCTs having patients with hypertrophic cardiomyopathy. • RCTs with patients being treated with Cardiac Myosin Inhibitors either Mavacamten or Aficamten compared with placebo
Exclusion	<ul style="list-style-type: none"> • Any observational study, retrospective cohort, conference paper and animal

Criteria	<div>studies.</div> <ul style="list-style-type: none">● Patients not having Cardiac Myosin Inhibitors as the intervention● Non-English Language Articles and non-randomized, one-arm studies
----------	---